Acessibilidade / Reportar erro

Risk and protective factors of acute respiratory infections in infants

Abstracts

OBJECTIVE: To analyze the effectiveness of maternal pneumococcal polysaccharide vaccine and the risk and protective factors for acute respiratory infections in infants. METHODS: Nested cross-sectional study of a clinical trial evaluating children of 139 women selected in a public prenatal care unit in the municipality of São Paulo, Southeastern Brazil, from 2005 to 2006. Subjects were randomly assigned to three groups: non-immunized (n=46); immunized with pneumococcal polysaccharide vaccine in the last trimester of pregnancy (n=42); and immunized with the vaccine immediately after childbirth (n=45). Infants were followed up for infections presumably caused by pneumococcus at the age of three and six months and nasopharyngeal samples were collected. Risk factors such as smokers living in the same household, siblings and exclusive maternal breastfeeding were investigated. RESULTS: The pneumococcal polysaccharide vaccine did not provide protection against pneumococcus infections. However, exclusive maternal breastfeeding until the age of six months protected infants against respiratory infections (OR= 7.331). Pneumococcal nasopharyngeal colonization at the age of three or six months increased the likelihood of occurrence of respiratory infections (OR= 2.792). CONCLUSIONS: Exclusive breastfeeding for six months protects infants against presumably pneumococcal infections regardless of pneumococcal vaccination.

Pneumococcal Vaccines; Vaccination; Pregnant Women; Prenatal Care; Immunity, Maternally-Acquired; Infant Welfare; Pneumococcal Infections; Cross-Sectional Studies


OBJETIVO: Analisar a efetividade da vacina pneumocócica polissacarídica e fatores de risco e proteção para infecções por pneumococo em lactentes. MÉTODOS: Estudo transversal aninhado em ensaio clínico com filhos de 139 mulheres selecionadas no pré-natal um serviço público de saúde em São Paulo, SP, de 2005 a 2006. As participantes foram randomizadas em três grupos: o primeiro não recebia nenhuma vacina (n=46), o segundo recebia a vacina pneumocócica polissacarídica no último trimestre de gravidez (n=42), e o terceiro a recebia no pós-parto imediato (n=45). As infecções presumivelmente causadas pelo pneumococo nos lactentes foram acompanhados aos três e seis meses de vida e colhidas amostras de nasofaringe. Foram investigados fatores de risco como: fumantes no domicílio, outras crianças no domicílio e aleitamento materno exclusivo. RESULTADOS: A vacina pneumocócica polissacarídica não mostrou proteção contra infecções causadas por pneumococo. No entanto, o aleitamento materno exclusivo até os seis meses protegeu os lactentes contra as infecções respiratórias (OR= 7,331). A colonização da nasofaringe por pneumococo aos três ou seis meses aumentou a chance de infecções respiratórias (OR= 2,792). CONCLUSÕES: Lactentes amamentados exclusivamente com leite materno até seis meses são significativamente protegidos contra infecções por pneumococos, independentemente da vacinação pneumocócica.

Cuidado Pré-Natal; Imunidade Materno-Adquirida; Bem-Estar do Lactente; Infecções Pneumocócicas; Estudos Transversais


OBJETIVO: Analizar la efectividad de la vacuna pneumocóccica polisacarídica y factores de riesgo y protección para infecciones por pneumococo en lactantes. MÉTODOS: Estudio transversal anidado en ensayo clínico con hijos de 139 mujeres seleccionadas en el prenatal en servicio público de salud en Sao Paulo, SP, de 2005 a 2006. Las participantes fueron aleatorizadas en tres grupos: el primero no recibía ninguna vacuna (n=46), el segundo recibía la vacuna pneumocóccica polisacarídica en el último trimestre del embarazo (n=42), y el tercero la recibía en el posparto inmediato (n=45). Las infecciones presumiblemente causadas por el pneumococo en los lactantes fueron acompañadas a los tres y seis meses de vida y colectadas muestras de nasofaringe. Fueron investigados factores de riesgo como: fumadores en el domicilio, otros niños en el domicilio y amamantamiento materno exclusivo. RESULTADOS: La vacuna pneumocóccica polisacarídica no mostró protección contra infecciones causadas por pneumococo. Sin embargo, el amamantamiento materno exclusivo hasta los seis meses protegió los lactantes contra las infecciones respiratorias (OR=7,331). La colonización de la nasofaringe por pneumococo a los tres o seis meses aumentó la probabilidad de infecciones respiratorias (OR=2,792). CONCLUSIONES: Lactantes amamantados exclusivamente con leche materna hasta los seis meses son significativamente protegidos contra infecciones por pneumococos, independientemente de la vacunación pneumocóccica.


ORIGINAL ARTICLES

Claudia Regina Cachulo LopesI; Eitan N BerezinII

IPrograma de Pós-graduacão em Pediatria. Santa Casa de Misericórdia de São Paulo. São Paulo, SP, Brasil

IIDepartamento de Pediatria. Faculdade de Ciências Médicas. Santa Casa de Misericórdia de São Paulo. São Paulo, SP, Brasil

Correspondence

ABSTRACT

OBJECTIVE: To analyze the effectiveness of maternal pneumococcal polysaccharide vaccine and the risk and protective factors for acute respiratory infections in infants.

METHODS: Nested cross-sectional study of a clinical trial evaluating children of 139 women selected in a public prenatal care unit in the municipality of São Paulo, Southeastern Brazil, from 2005 to 2006. Subjects were randomly assigned to three groups: non-immunized (n=46); immunized with pneumococcal polysaccharide vaccine in the last trimester of pregnancy (n=42); and immunized with the vaccine immediately after childbirth (n=45). Infants were followed up for infections presumably caused by pneumococcus at the age of three and six months and nasopharyngeal samples were collected. Risk factors such as smokers living in the same household, siblings and exclusive maternal breastfeeding were investigated.

RESULTS: The pneumococcal polysaccharide vaccine did not provide protection against pneumococcus infections. However, exclusive maternal breastfeeding until the age of six months protected infants against respiratory infections (OR= 7.331). Pneumococcal nasopharyngeal colonization at the age of three or six months increased the likelihood of occurrence of respiratory infections (OR= 2.792).

CONCLUSIONS: Exclusive breastfeeding for six months protects infants against presumably pneumococcal infections regardless of pneumococcal vaccination.

Descriptors: Pneumococcal Vaccines, administration & dosage. Vaccination. Pregnant Women. Prenatal Care. Immunity, Maternally-Acquired. Infant Welfare. Pneumococcal Infections, prevention & control. Cross-Sectional Studies.

RESUMEN

OBJETIVO: Analizar la efectividad de la vacuna pneumocóccica polisacarídica y factores de riesgo y protección para infecciones por pneumococo en lactantes.

MÉTODOS: Estudio transversal anidado en ensayo clínico con hijos de 139 mujeres seleccionadas en el prenatal en servicio público de salud en Sao Paulo, SP, de 2005 a 2006. Las participantes fueron aleatorizadas en tres grupos: el primero no recibía ninguna vacuna (n=46), el segundo recibía la vacuna pneumocóccica polisacarídica en el último trimestre del embarazo (n=42), y el tercero la recibía en el posparto inmediato (n=45). Las infecciones presumiblemente causadas por el pneumococo en los lactantes fueron acompañadas a los tres y seis meses de vida y colectadas muestras de nasofaringe. Fueron investigados factores de riesgo como: fumadores en el domicilio, otros niños en el domicilio y amamantamiento materno exclusivo.

RESULTADOS: La vacuna pneumocóccica polisacarídica no mostró protección contra infecciones causadas por pneumococo. Sin embargo, el amamantamiento materno exclusivo hasta los seis meses protegió los lactantes contra las infecciones respiratorias (OR=7,331). La colonización de la nasofaringe por pneumococo a los tres o seis meses aumentó la probabilidad de infecciones respiratorias (OR=2,792).

CONCLUSIONES: Lactantes amamantados exclusivamente con leche materna hasta los seis meses son significativamente protegidos contra infecciones por pneumococos, independientemente de la vacunación pneumocóccica.

INTRODUCTION

Acute respiratory infections are a major cause of morbidity in children especially in infants younger than six months. Nasopharyngeal colonization with Streptococcus pneumoniae can lead to invasive respiratory infections.4 The main pathogenic bacteria of acute respiratory infections is pneumococcus.

In developing countries it is estimated that pneumococcus causes more than 1 million death a year in children under five, mostly due to pneumonia,11,15,16,22 at a rate of two children dying per hour in Latin America. In 2007, pneumococcal disease killed 8,000 children in Brazil.

In Brazil, 30% of children under two are colonized with S. pneumoniae.1,4,10,21 The rate of pneumococcal nasopharyngeal colonization (PNC) in infants attending child day care centers is about 60%.17 A recent study showed that children exposed to smoking were more likely to have their nasopharynx colonized with acute middle ear infection pathogens (Moraxella catarrhalis, Haemophilus influenzae, and pneumococcus).20

Immunization of children against S. pneumoniae with conjugated vaccines proved effective against PNC. However, these are still costly vaccines for widespread use in health services. Immunization of pregnant woman against S. pneumoniae aimed to increase antibodies in infants may be an effective approach to protect these children during the first months of life.13,16

The objective of the present study was to analyze the effectiveness of maternal pneumococcal polysaccharide vaccine and to assess risk and protective factors for acute respiratory infections in infants.

METHODS

Nested cross-sectional study of a clinical trial evaluating children of 139 women selected in a public prenatal care unit in São Paulo, Southeastern Brazil, from May 2005 to January 2006. Pregnant women were consecutively interviewed as they arrived at the clinic and included in the study after they agreed to participate.

There were examined data from a larger study

Infants were underwent monthly evaluations during the first six months of life. During a routine pediatric visit they were checked for diseases such as acute middle ear infection (MEI), broncopneumonia (BCP) or any other invasive disease caused by S. pneumoniae. Diagnosis of MEI was clinically made by a physician in the emergency room. Diagnosis of BCP was clinically made but required radiological confirmation showing lobar, segmental or interstitial images of pneumonia. The principal investigator monitored most diagnoses and clinical follow-up of infants.

During the visits the mothers were asked about their infant's feeding, especially regarding exclusive breastfeeding and attendance of a day care center, which are both known risk and protective factors for pneumococcal disease, respectively.14,18 In addition to these variables, antibiotic use was assessed, even when there was no definite diagnosis.

The association between risk and/or protective factors and pneumococcal disease (BCP/MEI) or nasopharyngeal colonization was assessed using the chi-square test or Fisher's exact test. A 5% significance level was set. A multiple logistic regression analysis was performed to assess the combined effect of risk factors on disease occurrence. Variables with p<0.20 in the bivariate analysis were included in the multivariate model. The backward maximum likelihood method was used for selecting variables that might be better predictors of the outcome. Odds ratios (OR) and their related 95% confidence intervals were estimated in the final model. Epi Info 3.1 and SPSS 13.0 were used in the statistical analyses.

The study was approved by the Research Ethics Commitee of Santa Casa de São Paulo. All subjects signed a free informed consent form.

RESULTS

No difference of disease prevalence was found between immunized and non-immunized women (Table 1).

The rate of PNC in infants at the age of three and six months was 17.2% (24/139), and 16.5% (22/133), respectively. The prevalence of PNC in at least one time point at three or six months was 27% (36/133). The rate of penicillin resistance was 25% (6/24) and 40.9% (9/22) at three and six months of age, respectively.

The association between nasopharyngeal colonization at three months and disease (MEI/BCP) was not statistically significant (p=0.34). At six months of age, 23 infants had disease, of which 34.8% (8) were colonized while 12.7% of those did not have disease were colonized (p=0.015). No infant developed invasive disease.

Table 1 shows the distribution of children with and without disease (MEI/BCP), by risk and protective factors, during the first six months of life.

The associations between disease and the following risk or protective factors were significant: smokers and children under five living in the household; nasopharyngeal colonization by a resistant strain at the age of three or six months; and no exclusive breastfeeding by the age of three or six months.

In the multivariate analysis, the variable "living with other children under five" (p<0.20) was added. For adjusting the logistic regression model the variable "disease (MEI/BCP) by the age of six month" was selected.

The following variables were selected through the backward method: nasopharyngeal colonization at three or six months of age; living with other children under five; and no exclusive breastfeeding.

Children who were not on exclusive breastfeeding by six months of age were found to be seven times more likely to develop disease (Table 2). Nasopharyngeal colonization with S. pneumoniae at three or six months of age increased the risk of disease (MEI/BCP) by about three folds. Living with other children under five in the same household also increased the likelihood of disease (OR= 2.69, 95% CI: 1.00;7.27).

The model was sensitive as it correctly detected 97.3% (107/110) of children who did not develop disease. However, it was not specific as only 13% (3/23) of those children who developed disease were correctly identified.

No statistically significant association was seen between antibiotic use by the age of three months and colonization with resistant S. pneumoniae by the age of three (p=0.59) or six months (p=0.13).

DISCUSSION

Among strategies to reduce pneumococcal disease during childhood, the single proven effective measure is the administration of a conjugated vaccine against S. pneumoniae.2,3,6,8,9,19

Exclusive breastfeeding for six months was the single factor that contributed most to prevent pneumococcal disease leading to a 7-fold reduction in the risk of respiratory disease. Nasopharyngeal colonization with S. pneumoniae was a predisposing factor for disease development. It occurs before disease and interventions that can reduce nasopharyngeal colonization might reduce the likelihoood of disease. However, a study conducted in Pittsburg (US) reported that exclusive breastfeeding did not have an effect on PNC.14

Maternal immunization during pregnancy might be a prevention strategy. However, consistent with other studies,5,7,12,16 our study did not find vaccination of pregnant women effective to protect against colonization or infection.

Penicillin resistance of S. pneumoniae has increased worldwide and its main predisposing factor is antibiotic use. We did not find any statistically significant association between antibiotic use by the age of three months and nasopharyngeal colonization with resistant pneumococcus at three or six months of age.

Exclusive breastfeeding proved to be a major factor for reducing colonization and thus reducing pneumococcal disease during the first six months of life.

REFERENCES

  • 1. Berezin EN, Cardenuto MD, Otsuka M, Ferreira LL, Otsuka M, Guerra ML, et al. Distribution of Streptococcus pneumoniae serotypes in nasopharyngeal carriage and in invasive pneumococcal disease in Sao Paulo, Brazil. Pediatr Infect Dis J 2007:26(7);643-44. DOI:10.1097/INF.0b013e3180616d0f
  • 2. Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infct Dis J 2004;23(6):485-9. DOI:10.1097/01.inf.0000129685.04847.94
  • 3. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, et al. Effectiveness of hepavalent pneumococcal conjugate vaccine in children younger than five years of age for prevetion of pneumonia. Pediatr Infect Dis J 2002;21(9):810-5. DOI:10.1097/00006454-200209000-00005
  • 4. Bogaer D, De Groot R, Hermans PW. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect Dis 2004;4(3):144-54.DOI:10.1016/S1473-3099(04)00938-7
  • 5. Carvalho BT, Sampaio MMC, Sole D, Naspitz C, Leiva LE, Sorensen RU. Tranplacental transmission of serotype-specitis penumoccocal antibodies in Brazilian population. Clin Diagn Lab Immunol 1999;6(1):50-4.
  • 6. Centers for Disease Control and Prevetion. Direct and indirect effects of routine vaccination of children with 7 valent pneumococcal conjugate vaccine on incidene of invasive pneumococcal disease- United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54(36):893-7.
  • 7. Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, Lumbiganon P, Desimone JA, Baxter J, et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2006;25(1):CD004903.
  • 8. Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9- valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis 2005;192(3):367-76. DOI:10.1086/431679
  • 9. Eskola J, Kilpi T, Palmu A, Palmu A, Jokinen J, Haapakoski J, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344(6):403-9. DOI:10.1056/NEJM200102083440602
  • 10. Ferreira LLM, Carvalho ES, Berezin EM, Brandileone MC. Colonização e resistência antimicrobiana e Streptococcus pneumoniae isolado em nasofaringe de crianças com rinofaringite aguda. J Pediatr (Rio J) 2001;77(3):227-34. DOI:10.1590/S0021-75572001000300014
  • 11. Gray RM, Converse 3rd, GM Dillon Jr. HC. Epidemiologic studies of S. pneumoniae in infants acquisition carriage, and infection during the first 24 months of life. J Infect Dis 1988;142(6):923-33.
  • 12. Greenwood B. Maternal immunisation in developing countries.Vaccine 2003;21(24):3436-41.
  • 13. Jones VF, Harrison C, Stout GG, Hopkins J. Nasopharyngeal Colonization with heptavalent pneumococcal conjugate vaccine serotypes of Streptoccus pneumoniae with prolonged vaccine dosing intervals. Pediatr Infect Dis J 2005;24(11):969-73. DOI:10.1097/01.inf.0000187030.83080.8a
  • 14. Kaleida P, Nativio GD, Chao H, Cowden NS. Prevalence of bacterial respiratory pathogens in the nasopharynx in breast-fed versus formula-fed infants. J Clin Microbiol 1993;31(10):2674-8.
  • 15. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis 1981;3(2):246-53.
  • 16. Lehmann D, Pomat WS, Combs B, Dyke T, Alpens MP. Maternal immunization with pneumococcal polysaccharide vaccine in the highland of Papua New Guinea. Vaccine 2002;20(13-14):1837-45. DOI:10.1016/S0264-410X(02)00040-3
  • 17. Lucarevschi BR, Baldacci ER, Bricks LF, Bertoli CJ, Teixeira LM, Mendes CMF, et al. Colonização da orofaringe de crianças por Streptococcus pneumoniae em crianças de crèche de Taubaté(SP): correlação entre os principais sorotipos e a vacina conjugada heptavalente. J Pediatr (Rio J) 2003;79(3):215-20. DOI:10.1590/S0021-75572003000300006
  • 18. Mulholland K. Maternal immunization for the prevention of bacterial infection in young infants. Vaccine 1998;16(14-15):1464-67. DOI:10.1016/S0264-410X(98)00109-1
  • 19. O'Brien KL, Morilton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven valent conjugate pneumococcal vaccine in American Indian children : group randomized trial. Lancet 2003;362(9381):355-61. DOI:10.1016/S0140-6736(03)14022-6
  • 20. Raymond J, Le Thomas I, Moulin F, Commeau A, Gendret D, Berche P. Sequential colonization by Streptococcus pneumoniae of Health children living in an orphanage. J Infect Dis 2000;181(6):1983-8. DOI:10.1086/315505
  • 21. Rey LC, Wolf B, Moreira JLB, Verhoef J, Farhat CK. S. pneumoniae isolados da nasofaringe de crianças sadias e com pneumonia: taxa de colonização e suscetibilidade aos antimicrobianos. J Pediatr (Rio J) 2002;78(2):105-12. DOI:10.1590/S0021-75572002000200008
  • 22. World Health Organization. Etiology and clinical signs of serious infections in young infants in developing countries: a WHO collaborative study. Pediatr Infect Dis J. 1999;18(Suppl):561-9.
  • Risk and protective factors of acute respiratory infections in infants

    Factores de riesgo y protección de la infección respiratoria aguda en lactantes
  • ª
    The main predisposing factors for respiratory infections are: attendance of child day care centers, passive smoking, children of mothers with low schooling, overcrowding, and early termination of breastfeeding. Infants with these factors are more likely to develop respiratory infections, particularly S. pneumoniae infections.4
  • b
    conducted with pregnant women and children to assess the effectiveness of a 23-valent pneumococcal polysaccharide vaccine (PPV) offered during pregnancy. Pregnant women after week 28 of pregnancy without any major obstetrical conditions were randomly assigned to three groups during a routine low-risk prenatal care visit. Of 150 pregnant women recruited, 139 infants were followed up at the age of three months. There were excluded from the analysis six women as they did not complete all infant visits at six months of age and 133 mother-infant pairs remained in the study. Of these, 87 mothers had been immunized with PPV either during pregnancy or puerperium and 46 had not been immunized. During the initial interview, information on risk factors for pneumococcal infection, number of people and children (under five) living in the same household, presence of smokers and attendance of a child day care center was collected.
  • Publication Dates

    • Publication in this collection
      18 Dec 2009
    • Date of issue
      Dec 2009

    History

    • Accepted
      18 May 2009
    • Reviewed
      06 Dec 2008
    • Received
      28 Apr 2008
    Faculdade de Saúde Pública da Universidade de São Paulo Avenida Dr. Arnaldo, 715, 01246-904 São Paulo SP Brazil, Tel./Fax: +55 11 3061-7985 - São Paulo - SP - Brazil
    E-mail: revsp@usp.br